Articles tagged "Co-stimulation"

2016 American Transplant Congress
Targeting IFN-g-Expressing TIM-4⁺B Effector (Beff) Cells as a Novel Strategy to Prevent Allograft Rejection.
Q. Ding,¹ K. Mohib,¹ S. Xiao,² V. Kuchroo,² D. Rothstein.¹
¹University of Pittsburgh, Pittsburgh; ²Harvard Medical School, Boston.
B cell depletion can augment or inhibit auto- and allo- immune responses in humans and mice without altering Ig levels. This is likely due to…
2016 American Transplant Congress
The Role and Mechanism of CD40/CD40L Expression on Different T-Cell Subsets.
N. Granofszky, K. Hock, B. Mahr, N. Pilat-Michalek, T. Wekerle.
Department of Surgery, Section of Transplantation Immunology, Medical University of Vienna, Vienna, Austria.
Background: Several T-cell costimulatory pathways (i.e. CD28:B7 and CD40:CD40L) play a critical role in modulating alloreactivity, but their function on distinct T cell subsets remains…
2016 American Transplant Congress
Preservation of Alloreactive and Antiviral Immunity After Switch to Belatacept-Based Regimen After Kidney Transplantation.
J. Schaenman,¹ Y. Korin,² T. Sidwell,² V. Groysberg,² J. Gadzhyan,¹ E. Lum,¹ U. Reddy,¹ E. Huang,¹ T. Pham,¹ G. Danovitch,¹ E. Reed,² S. Bunnapradist.¹
¹Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Department of Pathology, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Purpose: We set out to investigate the impact of switch from calcineurin inhibitor (CNI) to belatacept on T cell mediated allo- and EBV-specific immunity.Methods: We…
2016 American Transplant Congress
Inhibitory FcγRIIB Functionally Inhibits Donor-Reactive CD8⁺ Memory T Cell Responses Following Transplantation.
D. Pinelli, M. Wagener, D. Liu, I. Badell, M. Ford.
Emory Transplant Center, Emory University, Atlanta, GA.
Fc receptors are expressed by many types of immune cells and bind to the constant portion of immunoglobulin to mediate their effector functions. The inhibitory…
2016 American Transplant Congress
Peritransplant Costimulation Blockade Combined with a Short-Course of Rapamycin Prevents Rejection of Vascularized Composite Allografts.
B. Oh, G. Furtmüller, M. Fryer, P. Akre, D. Cooney, W. Lee, G. Raimondi, G. Brandacher.
Department of Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
[Background] Reconstructive transplantation represents a valid therapeutic option after devastating tissue loss. Routine clinical application, however, is hampered by the toxicity of long-term maintenance immunosuppression.…
2016 American Transplant Congress
Conversion to Belatacept as Rescue Therapy in Kidney Transplant Recipients with Severe Graft Dysfunction.
F. Oldhafer,¹ M. Hiss,² A. Schwarz,² H. Haller,² G. Einecke.²
¹Clinic for General, Abdominal and Transplant Surgery, Hannover Medical School, Hannover, Germany; ²Clinic for Nephrology, Hannover Medical School, Hannover, Germany.
Belatacept is a fusion protein that prevents T cell co-stimulation via the CD28 receptor. If used as first-line therapy, immunosuppression with Belatacept is associated with…
2016 American Transplant Congress
Lymph Node Stromal Laminins Differentially Regulate T Cell Immunity and Tolerance.
T. Simon, J. Bromberg.
University of Maryland, Baltimore, MD.
Background:Our recent work demonstrated that laminins α4β1γ1 and α5β1γ1, components of the lymph node (LN) stroma, are differentially regulated. Tolerance is associated with relatively higher…
2016 American Transplant Congress
Tolerance Induction in Vascularized Composite Allotransplantation with Peri-Transplant Combined Costimulation Blockade.
B. Oh,¹ G. Furtmüller,¹ M. Fryer,¹ J. Grahammer,² S. Schneeberger,² D. Cooney,¹ G. Raimondi,¹ G. Brandacher.¹
¹Department of Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD; ²Department of Visceral, Transplant and Thoracic Surgery, Innsbruck Medical University, Innsbruck, Austria.
[Background] Vascularized composite allotransplantation (VCA) is an emerging new era in transplant medicine and has become a valid therapeutic option after devastating tissue loss, such…
2016 American Transplant Congress
Belatacept Conversion in Adult Kidney Transplant Recipients for Cause: A Single Center Observational Cohort.
M. Savic,¹ M. Cruz,² A. Rossi,¹ J. Vella.¹
¹Maine Transplant Program, Maine Medical Center, Portland, ME; ²University of Connecticut, Storrs, CT.
Background: Calcineurin inhibition (CNI) is the single most effective strategy to prevent allograft rejection however tolerability is limited by toxicity. To date, alternate strategies have…
2016 American Transplant Congress
Successful Treatment of Established Acute Allograft Rejection with Delayed CTLA-4Ig.
J. Young,¹ J. Chen,¹ D. Yin,¹ R. Sciammas,² V. Vu,¹ M.-L. Alegre,³ A. Chong.¹
¹Transplant Surgery, University of Chicago, Chicago, IL; ²Medicine, Houston Methodist Research Institute, Houston, TX; ³Medicine, University of Chicago, Chicago, IL.
Purpose: Our goal was to determine the efficacy and immune mechanisms of costimulation blockade by CTLA-4Ig when treatment begins after an immune response is already…